On June 3, 2022, Frank L. Jaksch, Jr. notified ChromaDex Corporation of his intention to resign as executive director and employee of the Company and as an officer, employee, and director of any subsidiaries of the Company in which he serves in any of those capacities. Mr. Jaksch will continue to serve on the board of directors of the Company and as chairman of the Board. The effective date of Mr. Jaksch's resignation is June 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.98 USD | -6.88% | -6.88% | +108.39% |
Jun. 13 | Chromadex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® | CI |
Jun. 07 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+108.39% | 226M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- CDXC Stock
- News ChromaDex Corporation
- ChromaDex Corporation Announces Resignation of Frank L. Jaksch, Jr as Executive Director, with Effect from June 30, 2022